Get the Stockscreener App
344.57
1.01%
3.46
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $344.57, with a volume of 2.33M.
It is up +1.01% in the last 24 hours and up +18.10% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$341.11
Open:
$341.525
24h Volume:
2.33M
Relative Volume:
0.91
Market Cap:
$185.54B
Revenue:
$35.89B
Net Income/Loss:
$7.01B
P/E Ratio:
26.64
EPS:
12.9352
Net Cash Flow:
$11.54B
1W Performance:
+0.63%
1M Performance:
+18.10%
6M Performance:
+26.84%
1Y Performance:
+23.06%
1-Day Range:
$340.00
$345.03
1-Week Range:
$331.70
$345.09
52-Week Range:
$253.30
$345.84
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
344.57 | 183.68B | 35.89B | 7.01B | 11.54B | 12.94 |
|
LLY
Lilly Eli Co
|
1,104.34 | 993.42B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
207.56 | 497.93B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
227.66 | 409.68B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
130.44 | 249.94B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
104.63 | 262.25B | 63.90B | 19.05B | 13.05B | 7.5596 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
What is Zacks Research's Estimate for Amgen FY2025 Earnings? - MarketBeat
Boston Partners Has $209.05 Million Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Verity & Verity LLC Grows Stock Position in Amgen Inc. $AMGN - MarketBeat
Steward Partners Investment Advisory LLC Has $21.08 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen prevails over Sanofi at UPC Court of Appeal with Brinkhof and Bardehle - JUVE Patent
North Star Asset Management Inc. Raises Holdings in Amgen Inc. $AMGN - MarketBeat
XTX Topco Ltd Has $3.01 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Manchester Capital Management LLC Decreases Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Oak Associates Ltd. OH Acquires 2,410 Shares of Amgen Inc. $AMGN - MarketBeat
Laurel Wealth Advisors LLC Purchases 6,676,575 Shares of Amgen Inc. $AMGN - MarketBeat
Jaffetilchin Investment Partners LLC Sells 1,262 Shares of Amgen Inc. $AMGN - MarketBeat
J.W. Cole Advisors Inc. Increases Stock Position in Amgen Inc. $AMGN - MarketBeat
Global Retirement Partners LLC Invests $4.31 Million in Amgen Inc. $AMGN - MarketBeat
RiverFront Investment Group LLC Takes $680,000 Position in Amgen Inc. $AMGN - MarketBeat
The Zacks Analyst Blog NVIDIA, AT&T and Amgen - sharewise.com
Cornerstone Capital Inc. Cuts Stock Position in Amgen Inc. $AMGN - MarketBeat
How FDA Approval and New Guidelines for IMDELLTRA Could Shape Amgen (AMGN) Investor Expectations - simplywall.st
Top Analyst Reports for NVIDIA, AT&T & Amgen - MSN
Teva obtient les autorisations de la Commission européenne pour PONLIMSI® (dénosumab), biosimilaire de Prolia® et DEGEVMA® (dénosumab), biosimilaire de Xgeva® - GlobeNewswire Inc.
Truist Financial Initiates Coverage on Amgen (NASDAQ:AMGN) - MarketBeat
Is Amgen Stock Underperforming the Nasdaq? - Barchart.com
Investors in Amgen (NASDAQ:AMGN) have seen decent returns of 76% over the past five years - Yahoo Finance
Amgen Inc. $AMGN Position Lifted by DCF Advisers LLC - MarketBeat
Edgar Lomax Co. VA Sells 2,115 Shares of Amgen Inc. $AMGN - MarketBeat
Biotech Drug Market Set for Dynamic Boom as Key Players Amgen, - openPR.com
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - sharewise.com
Amgen at the Milken Future of Health Summit 2025 - Amgen
Amgen (NASDAQ: AMGN) to Join Citi 2025 Global Healthcare Conference on Dec. 3 - Stock Titan
AMGEN TO PRESENT AT THE 8TH ANNUAL EVERCORE ISI HEALTHCONX CONFERENCE - MarketScreener
Amgen (NASDAQ: AMGN) to webcast Evercore ISI HealthCONx presentation Dec. 3 - Stock Titan
Amgen (AMGN) Rating Update: Truist Securities Raises Price Targe - GuruFocus
Here's Why Amgen (AMGN) is a Strong Momentum Stock - sharewise.com
Prudential Financial Inc. Boosts Position in Amgen Inc. $AMGN - MarketBeat
1,378 Shares in Amgen Inc. $AMGN Acquired by Private Management Group Inc. - MarketBeat
Amgen Inc. $AMGN Shares Sold by Mediolanum International Funds Ltd - MarketBeat
Hillsdale Investment Management Inc. Purchases New Shares in Amgen Inc. $AMGN - MarketBeat
Charles Schwab Investment Management Inc. Has $3.60 Billion Position in Amgen Inc. $AMGN - MarketBeat
Coldstream Capital Management Inc. Increases Position in Amgen Inc. $AMGN - MarketBeat
Amgen Insider Sold Shares Worth $1,058,667, According to a Recent SEC Filing - MarketScreener
Regeneron Moves To Strike And Dismiss Amgen's Counterclaims In Aflibercept Litigation - MarketScreener
Amgen Inc Reports Strong Q3 Earnings and Strategic Growth - MSN
Rhumbline Advisers Reduces Holdings in Amgen Inc. $AMGN - MarketBeat
Mufg Securities Americas Inc. Increases Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Stock Position Decreased by Neo Ivy Capital Management - MarketBeat
Amgen Inc. $AMGN Shares Sold by Bahl & Gaynor Inc. - MarketBeat
Amgen Inc. $AMGN Shares Sold by Bank Julius Baer & Co. Ltd Zurich - MarketBeat
Amgen Inc. (AMGN): A Bull Case Theory - MSN
Amgen (NASDAQ:AMGN) SVP Nancy Grygiel Sells 3,139 Shares - MarketBeat
Amgen SVP Grygiel sells $1.05 million in AMGN stock By Investing.com - Investing.com Nigeria
[Form 4] AMGEN INC Insider Trading Activity - Stock Titan
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.51%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):